Among patients with Alzheimer disease, more than 90% experience neuropsychiatric symptoms during the course of their illness1 with agitation one of the most frequent and clinically important symptoms. Agitation is not only distressing for the patient but often confers risk both to patients and to others (such as family members and caregivers). Agitation also represents a common trigger for institutionalization and presents a major management challenge for clinicians. Effective treatment options for agitation in patients with Alzheimer disease are limited, so clinical innovation in this area is a high priority.
Ballard C, Sharp S, Corbett A. Dextromethorphan and Quinidine for Treating Agitation in Patients With Alzheimer Disease Dementia. JAMA. 2015;314(12):1233–1235. doi:10.1001/jama.2015.10215
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: